Effects of Androgen Administration in Men with the AIDS Wasting Syndrome

Steven Grinspoon(Textron Systems (United Kingdom)), Colleen Corcoran(Textron Systems (United Kingdom)), Hassan Askari(Textron Systems (United Kingdom)), David Schoenfeld(Textron Systems (United Kingdom)), Lisa Wolf(Textron Systems (United Kingdom)), Belton A. Burrows(Textron Systems (United Kingdom)), Mark Walsh(Textron Systems (United Kingdom)), Douglas Hayden(Textron Systems (United Kingdom)), Kristin Parlman(Textron Systems (United Kingdom)), Ellen Anderson(Textron Systems (United Kingdom)), Nesli Basgoz(Textron Systems (United Kingdom)), Anne Klibanski(Textron Systems (United Kingdom))
Annals of Internal Medicine
July 1, 1998
Cited by 237

Abstract

BACKGROUND: Development of successful anabolic strategies to reverse the loss of lean body mass is of critical importance to increase survival in men with the AIDS wasting syndrome. Hypogonadism, an acquired endocrine deficiency state characterized by loss of testosterone, occurs in more than half of all men with advanced HIV disease. It is unknown whether testosterone deficiency contributes to the profound catabolic state and loss of lean body mass associated with the AIDS wasting syndrome. OBJECTIVE: To investigate the effects of physiologic testosterone administration on body composition, exercise functional capacity, and quality of life in androgen-deficient men with the AIDS wasting syndrome. DESIGN: Randomized, double-blind, placebo-controlled study. SETTING: University medical center. PATIENTS: 51 HIV-positive men (age 42 +/- 8 years) with wasting (body weight < 90% of ideal body weight or weight loss > 10% of baseline weight) and a free testosterone level less than 42 pmol/L (normal range for men 18 to 49 years of age, 42 to 121 pmol/L [12.0 to 35.0 pg/mL]). INTERVENTION: Patients were randomly assigned to receive testosterone enanthate, 300 mg, or placebo intramuscularly every 3 weeks for 6 months. MEASUREMENTS: Change in fat-free mass was the primary end point. Secondary clinical end points were weight, lean body mass, muscle mass, exercise functional capacity, and change in perceived quality of life. Virologic variables were assessed by CD4 count and viral load. RESULTS: Compared with patients who received placebo, testosterone-treated patients gained fat-free mass (-0.6 kg and 2.0 kg; P = 0.036), lean body mass (0.0 kg and 1.9 kg; P = 0.041), and muscle mass (-0.8 kg and 2.4 kg; P = 0.005). The changes in weight, fat mass, total-body water content, and exercise functional capacity did not significantly differ between the groups. Patients who received testosterone reported benefit from the treatment (P = 0.036), feeling better (P = 0.033), improved quality of life (P = 0.040), and improved appearance (P = 0.021). Testosterone was well tolerated in all patients. CONCLUSIONS: Physiologic testosterone administration increases lean body mass and improves quality of life among androgen-deficient men with the AIDS wasting syndrome.


Related Papers

No related papers found

Powered by citation graph analysis